Newsroom | IDEAYA Biosciences

News Alerts

Oct 8, 2019

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its first...
Aug 12, 2019

IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
Jul 11, 2019

IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2...
Jul 9, 2019

IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions...
May 28, 2019

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share. The gross...
May 22, 2019

IDEAYA Announces Pricing of Initial Public Offering

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before...
May 8, 2019

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the U.S. Food and Drug...
Mar 29, 2019

Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a...
Feb 13, 2019

IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointments of Frank...
Jan 2, 2019

IDEAYA Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the company is...

Show per page

News Releases